These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38726009)

  • 1. Editorial: Analysis of tumor immune microenvironments and molecular mechanism to reveal the dilemma of immunotherapy for advanced non-small cell lung cancer.
    Roviello G; Vascotto IA; Catalano M
    Front Immunol; 2024; 15():1415608. PubMed ID: 38726009
    [No Abstract]   [Full Text] [Related]  

  • 2. Lung cancer: potential targets for immunotherapy.
    Tartour E; Zitvogel L
    Lancet Respir Med; 2013 Sep; 1(7):551-63. PubMed ID: 24461616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy.
    Zheng H; Zeltsman M; Zauderer MG; Eguchi T; Vaghjiani RG; Adusumilli PS
    Immunotherapy; 2017 Sep; 9(11):913-927. PubMed ID: 29338609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.
    Leonetti A; Wever B; Mazzaschi G; Assaraf YG; Rolfo C; Quaini F; Tiseo M; Giovannetti E
    Drug Resist Updat; 2019 Sep; 46():100644. PubMed ID: 31585395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges.
    Xiang Y; Liu X; Wang Y; Zheng D; Meng Q; Jiang L; Yang S; Zhang S; Zhang X; Liu Y; Wang B
    Front Immunol; 2024; 15():1366260. PubMed ID: 38655260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunotherapy in non-small cell lung cancer patients: back to the future.].
    Roberto M; Botticelli A; Cecere F; Cognetti F; Giusti R; Gelibter A; Lugini A; Nelli F; Nuti M; Santini D; Marchetti P
    Recenti Prog Med; 2019 Dec; 110(12):587-593. PubMed ID: 31909761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in the treatment of non-small cell lung cancer.
    Bílek O; Bořilová S; Grell P; Kiss I
    Klin Onkol; 2021; 34(Supplementum 1):54-64. PubMed ID: 34154331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Immunometabolism Mediated by CD73 Pathway in
    Passarelli A; Aieta M; Sgambato A; Gridelli C
    Front Immunol; 2020; 11():1479. PubMed ID: 32760402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Predictive biomarkers for immune checkpoint inhibitors in non-small-cell lung cancer].
    Fu MJ; Zhou JY
    Zhonghua Jie He He Hu Xi Za Zhi; 2020 Feb; 43(2):87-91. PubMed ID: 32062877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context.
    Wiesweg M; Mairinger F; Reis H; Goetz M; Kollmeier J; Misch D; Stephan-Falkenau S; Mairinger T; Walter RFH; Hager T; Metzenmacher M; Eberhardt WEE; Zaun G; Köster J; Stuschke M; Aigner C; Darwiche K; Schmid KW; Rahmann S; Schuler M
    Eur J Cancer; 2020 Nov; 140():76-85. PubMed ID: 33059196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer.
    Santana-Davila R; Chow LQ
    Future Oncol; 2018 Feb; 14(3):191-194. PubMed ID: 29334785
    [No Abstract]   [Full Text] [Related]  

  • 12. Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer.
    Kakimi K; Nakajima J; Wada H
    Lung Cancer; 2009 Jul; 65(1):1-8. PubMed ID: 19062127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-33, a Potential Cytokine Expressed in Tumor Microenvironment Involves in Antitumor Immunotherapy Through Facilitates CD8
    Li X; Lv Q; Feng Y; Gu Y; Xia R; Ma J; He H; Zhu Y
    J Interferon Cytokine Res; 2018 Nov; 38(11):491-499. PubMed ID: 30452317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Promise of Neoadjuvant Immunotherapy in Resected Non-small Cell Lung Cancer].
    Yao S; Zhang Y
    Zhongguo Fei Ai Za Zhi; 2020 Jan; 23(1):55-59. PubMed ID: 31948539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. To Treat or Not to Treat: Role of Immunotherapy in Patients with Concomitant Diagnosis of Advanced-Stage Non-Small Cell Lung Cancer and Psoriasis.
    Khunger M; Calabrese C; Kontzias A; Velcheti V
    J Thorac Oncol; 2017 Sep; 12(9):e147-e149. PubMed ID: 28838717
    [No Abstract]   [Full Text] [Related]  

  • 16. Biomarkers for Immunotherapy.
    Bustamante-Alvarez JG; Owen DH
    Thorac Surg Clin; 2020 May; 30(2):207-214. PubMed ID: 32327179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer.
    Karasaki T; Nagayama K; Kuwano H; Nitadori JI; Sato M; Anraku M; Hosoi A; Matsushita H; Morishita Y; Kashiwabara K; Takazawa M; Ohara O; Kakimi K; Nakajima J
    J Thorac Oncol; 2017 May; 12(5):791-803. PubMed ID: 28088513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selecting patients for immune checkpoint inhibition in lung cancer.
    Garon EB
    Clin Adv Hematol Oncol; 2015 Aug; 13(8):490-2. PubMed ID: 26351808
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance.
    Pu X; Wu L; Su D; Mao W; Fang B
    BMC Cancer; 2018 Nov; 18(1):1082. PubMed ID: 30409126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy.
    Klein O; Kee D; Markman B; Carlino MS; Underhill C; Palmer J; Power D; Cebon J; Behren A
    Cancer Cell; 2021 May; 39(5):592-593. PubMed ID: 33930312
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.